133 related articles for article (PubMed ID: 31229042)
1. Interstitial nephritis in immune checkpoint inhibitor therapy.
Manohar S; Albright RC
Kidney Int; 2019 Jul; 96(1):252. PubMed ID: 31229042
[No Abstract] [Full Text] [Related]
2. Acute interstitial nephritis after sequential ipilumumab - nivolumab therapy of metastatic melanoma.
Bottlaender L; Breton AL; de Laforcade L; Dijoud F; Thomas L; Dalle S
J Immunother Cancer; 2017 Jul; 5(1):57. PubMed ID: 28716106
[TBL] [Abstract][Full Text] [Related]
3. Positron emission tomography as an adjuvant diagnostic test in the evaluation of checkpoint inhibitor-associated acute interstitial nephritis.
Qualls D; Seethapathy H; Bates H; Tajmir S; Heidari P; Endres P; Reynolds K; Lawrence D; Sise M
J Immunother Cancer; 2019 Dec; 7(1):356. PubMed ID: 31864416
[TBL] [Abstract][Full Text] [Related]
4. Histological diagnosis of immune checkpoint inhibitor induced acute renal injury in patients with metastatic melanoma: a retrospective case series report.
Hultin S; Nahar K; Menzies AM; Long GV; Fernando SL; Atkinson V; Cebon J; Wong MG
BMC Nephrol; 2020 Sep; 21(1):391. PubMed ID: 32894101
[TBL] [Abstract][Full Text] [Related]
5. Sweet syndrome associated with ipilimumab in a patient with metastatic melanoma.
Adler NR; Murray WK; Brady B; McCormack C; Pan Y
Clin Exp Dermatol; 2018 Jun; 43(4):497-499. PubMed ID: 29396853
[No Abstract] [Full Text] [Related]
6. Mediastinal FDG-positive lymph nodes simulating melanoma progression: drug-induced sarcoidosis like/lymphadenopathy related to ipilimumab.
González-Cruz C; Bodet D; Muñoz-Couselo E; García-Patos V
BMJ Case Rep; 2021 Jan; 14(1):. PubMed ID: 33509865
[TBL] [Abstract][Full Text] [Related]
7. Metastatic melanoma response to combination therapy with ipilimumab and vemurafenib.
Sachpekidis C; Hassel JC; Dimitrakopoulou-Strauss A
Hell J Nucl Med; 2017; 20(3):251-253. PubMed ID: 29177265
[TBL] [Abstract][Full Text] [Related]
8. Immune checkpoint inhibitor-induced granulomatosis with polyangiitis.
Hung W; Cusnir I; Habib S; Smylie M; Solez K; Yacyshyn E
Rheumatology (Oxford); 2021 Jun; 60(6):e190-e191. PubMed ID: 33367837
[No Abstract] [Full Text] [Related]
9. Secondary haemophagocytic lymphohistiocytosis due to checkpoint inhibitor therapy.
Chin CK; Hall S; Green C; Van Hazel G; Spagnolo D; Cheah CY
Eur J Cancer; 2019 Jul; 115():84-87. PubMed ID: 31129384
[No Abstract] [Full Text] [Related]
10. Granulomatous nephritis and dermatitis in a patient with BRAF V600E mutant metastatic melanoma treated with dabrafenib and trametinib.
Jansen YJ; Janssens P; Hoorens A; Schreuer MS; Seremet T; Wilgenhof S; Neyns B
Melanoma Res; 2015 Dec; 25(6):550-4. PubMed ID: 26512791
[TBL] [Abstract][Full Text] [Related]
11. Granulomatous interstitial nephritis associated with silica.
Nakata T; Suzuki M; Maruo M; Yamasaki Y; Ishida K; Kudo A; Hashinaga E; Aoki K; Higashi H; Nawata T; Fukunaga N; Hisano S; Shibata H
Nephrology (Carlton); 2018 Feb; 23(2):190. PubMed ID: 29346841
[No Abstract] [Full Text] [Related]
12. Critical renal adverse event induced by nivolumab therapy in a stage IV melanoma patient.
Tanaka A; Ikinaga K; Kiyohara E; Tanemura A; Wataya-Kaneda M; Fujimura R; Mizui M; Isaka Y; Katayama I
J Dermatol; 2017 Jun; 44(6):727-728. PubMed ID: 27461931
[No Abstract] [Full Text] [Related]
13. Balancing the Checkpoint: Managing Colitis Associated with Dual Checkpoint Inhibitors and High-Dose Aspirin.
Hammami MB; Gill R; Thiruvengadam N; Oh DY; Beck K; Mahadevan U; Kattah MG
Dig Dis Sci; 2019 Mar; 64(3):685-688. PubMed ID: 30778872
[No Abstract] [Full Text] [Related]
14. Thymic hyperplasia following double immune checkpoint inhibitor therapy in two patients with stage IV melanoma.
Mencel J; Gargett T; Karanth N; Pokorny A; Brown MP; Charakidis M
Asia Pac J Clin Oncol; 2019 Dec; 15(6):383-386. PubMed ID: 31373116
[TBL] [Abstract][Full Text] [Related]
15. Checkpoint inhibitor-induced sarcoid reaction mimicking bone metastases.
Jespersen H; Bjursten S; Ny L; Levin M
Lancet Oncol; 2018 Jun; 19(6):e327. PubMed ID: 29893264
[No Abstract] [Full Text] [Related]
16. Immune-mediated Disease in Ipilimumab Immunotherapy of Melanoma with FDG PET-CT.
Wachsmann JW; Ganti R; Peng F
Acad Radiol; 2017 Jan; 24(1):111-115. PubMed ID: 27818005
[TBL] [Abstract][Full Text] [Related]
17. Successful administration of ipilimumab to two kidney transplantation patients with metastatic melanoma.
Lipson EJ; Bodell MA; Kraus ES; Sharfman WH
J Clin Oncol; 2014 Jul; 32(19):e69-71. PubMed ID: 24493726
[No Abstract] [Full Text] [Related]
18. Successful treatment of immune checkpoint inhibitor-related periaortitis.
Bührer ED; Alberts IL; Christ L; Özdemir BC
Swiss Med Wkly; 2024 Feb; 154():3631. PubMed ID: 38579296
[TBL] [Abstract][Full Text] [Related]
19. 18F-FDG PET/CT longitudinal studies in patients with advanced metastatic melanoma for response evaluation of combination treatment with vemurafenib and ipilimumab.
Sachpekidis C; Kopp-Schneider A; Hakim-Meibodi L; Dimitrakopoulou-Strauss A; Hassel JC
Melanoma Res; 2019 Apr; 29(2):178-186. PubMed ID: 30653029
[TBL] [Abstract][Full Text] [Related]
20. [Stable disease or complete response? : A critical evaluation of the radiologic response to immune checkpoint blockade in advanced melanoma].
Tietze JK; Heppt M; Angelova D; Ruzicka T; Berger F; Berking C
Hautarzt; 2017 Aug; 68(8):632-638. PubMed ID: 28382381
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
